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OBJECTIVE — Depression is associated with poor glycemic control and complications in
people with type 1 diabetes. We assessed the prevalence of depression and antidepressant
medication use among adults with and without type 1 diabetes and the association between
depression and diabetes complications.
RESEARCH DESIGN AND METHODS — In 2006–2008, the Coronary Artery Calci-
ﬁcation in Type 1 Diabetes Study applied the Beck Depression Inventory II (BDI-II) to 458
participants with type 1 diabetes (47% male, aged 44  9 years, type 1 diabetes duration 29 
9 years) and 546 participants without diabetes (nondiabetic group) (51% male, aged 47  9
years). Use of antidepressant medication was self-reported. Depression was deﬁned as a BDI-II
score 14 and/or use of antidepressant medication. Occurrence of diabetes complications (ret-
inopathy, blindness, neuropathy, diabetes-related amputation, and kidney or pancreas trans-
plantation) was self-reported.
RESULTS — Mean BDI-II score, adjusted for age and sex, was signiﬁcantly higher in partic-
ipantswithtype1diabetesthaninnondiabeticparticipants(least-squaresmeanSE:7.40.3
vs. 5.0  0.3; P  0.0001). Type 1 diabetic participants reported using more antidepressant
medications (20.7 vs. 12.1%, P  0.0003). More type 1 diabetic than nondiabetic participants
were classiﬁed as depressed by BDI-II cut score (17.5 vs. 5.7%, P  0.0001) or by either BDI-II
cut score or antidepressant use (32.1 vs. 16.0%, P  0.0001). Participants reporting diabetes
complications (n  209) had higher mean BDI-II scores than those without complications
(10.7  9.3 vs. 6.4  6.3, P  0.0001).
CONCLUSIONS — Compared with nondiabetic participants, adults with type 1 diabetes
report more symptoms of depression and more antidepressant medication usage. Depression is
highly prevalent in type 1 diabetes and requires further study on assessment and treatment.
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T
ype 1 diabetes is a chronic illness
that requires continuing medical
care, education, and diligent patient
self-management to prevent acute com-
plications and to reduce the risk of long-
term complications. Yet many patients do
not achieve glycosylated hemoglobin
(GHb) levels 7.0%, the American Dia-
betes Association goal to prevent compli-
cations (1). Depression is a modiﬁable
risk factor whose treatment could im-
prove glycemic control and health out-
comes in patients with type 1 diabetes.
In people with diabetes, depression
has been associated with hyperglycemia
(2,3); lower levels of diabetes self-care
(2); complications, including coronary/
cardiovascular disease (4–7), neuropathy
(6,8), and retinopathy (3,6); and in-
creased mortality (9). However, few data
are available regarding prevalence of de-
pression in individuals with type 1 diabetes
compared with the general population. A
meta-analysis carried out by Anderson et
al. (10) led to the conclusion that the
prevalence of depression in adults with
any type of diabetes is double that of in-
dividualswithoutdiabetes.Sincethen,re-
sults from the 2006 Behavioral Risk
Factor Surveillance System (11) have
found the age-adjusted prevalence of ma-
jor depression in individuals with diabe-
tes to be 8.3%, while the estimated
prevalence of major depression in the
generalU.S.populationis5.3%(12).His-
lopetal.(13)foundthatoverone-thirdof
young adults with diabetes experience
psychological distress.
These ﬁndings must be interpreted
with caution, however. Many studies on
the subject of depression and diabetes
have methodological limitations such as
lack of control group, small sample size,
and failure to distinguish between type 1
and type 2 diabetes (10,14). Where there
is no control group, recruitment bias can
limit generalizability. Since type 1 and
type 2 diabetes differ considerably in
terms of age of onset, duration, day-to-
day management, presence of comorbid
conditions, and nature and onset of com-
plications, depression may affect the two
conditions differently and different pro-
cesses may be involved in the develop-
ment of depression in individuals with
type 1 and type 2 diabetes. Therefore, in-
ferences from combined groups may not
represent diabetes type-speciﬁc preva-
lence of depression. As an example, of 42
studies analyzed in the Anderson meta-
analysis, 22 (52%) did not use a control
group, and of 20 controlled studies, only
3 reported separate results for type 1 and
type 2 diabetes (10).
A recent review of the literature (14)
states that it is not yet possible to con-
cludethatdepressionismoreprevalentin
individuals with type 1 diabetes than in
age-matched control subjects due to
widely varying diagnostic techniques,
small sample sizes, inadequate control
groups, and failure to distinguish be-
tween types of diabetes in previous stud-
ies. In this study, we aimed to assess the
prevalence of depression deﬁned by self-
reported questionnaire and/or antide-
pressant drug use in a cohort of adults
withandwithouttype1diabetes.Wealso
aimed to conﬁrm previous ﬁndings sug-
gesting that depression is associated with
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tion(CAC),anddiabetescomplicationsin
adults with type 1 diabetes.
RESEARCH DESIGN AND
METHODS— The data presented in
this report were collected as part of the
third study visit in the Coronary Artery
Calciﬁcation in Type 1 Diabetes (CACTI)
Study from 2006 to 2008. At the time of
this analysis, 1,130 CACTI participants
had completed the third CACTI study
visit. Participants without diabetes were
recruited from the community and in-
clude spouses, neighbors, and friends of
type 1 diabetic participants to reduce po-
tential differences in socioeconomic and
educational factors. Questionnaires were
completed by 1,004 participants (88.9%
of third-visit participants), including 458
type 1 diabetic participants (47% male,
aged 44  9 years, type 1 diabetes dura-
tion 29  9 years) and 546 nondiabetic
participants (51% male, aged 47  9
years). One-hundred and twenty-six sub-
jects who did not complete the BDI-II
tended to be younger (42.0  8.5 vs.
45.5  9.0; P  0.0001) than those who
were included in the study but were not
different in terms of BMI, A1C, duration
of diabetes, or CAC.
The Beck Depression Inventory II
(BDI-II) is a 21-item self-report instru-
ment that assesses the severity of depres-
sive symptomatology in adolescents and
adults. It is a revised version of the origi-
nal BDI (15), updated to correspond to
criteria from the Diagnostic and Statistical
Manual of Mental Disorders (16). Each of
the 21 items measures the presence and
severity of a somatic or cognitive symp-
tom of depression, rated on a 4-point
scale ranging from 0 to 3. The ratings are
summed, yielding a total score that can
range from 0 to 63. The BDI-II has been
validated as a sensitive, speciﬁc, and pre-
dictive tool for measuring depression
(17). Despite the fact that the somatic
symptoms of preexisting medical condi-
tions such as diabetes may overlap those
of depression, studies have shown that
thesomaticitemsdonotinterferewiththe
discriminative capacity of the BDI-II in
primary-care settings (18) or in partici-
pants with diabetes (19). The BDI-II has
also been shown to be sensitive and spe-
ciﬁc at any phase of a depressive disorder
(20).
Useofantidepressantmedicationwas
self-reported (participants brought their
medications to the study visit for veriﬁca-
tion) and included use of selective seroto-
nin reuptake inhibitors, norepinephrine/
dopamine reuptake inhibitors, selective
serotonin/norepinephrine reuptake in-
hibitors, selective norepinephrine re-
uptake inhibitors (SNRIs), tetracyclic
antidepressants, and tricyclic antidepres-
sants. Depression was deﬁned as use of at
least one antidepressant medication and/
or, as in previous studies (3,5), a BDI-II
score 14. Occurrence of diabetes com-
plications (retinopathy, blindness, neu-
ropathy, diabetes-related amputation,
and kidney or pancreas transplantation)
was self-reported.
To assess CAC, all patients under-
went two electron-beam computed to-
mography scans within 5 min without
contrast at baseline and two scans at fol-
low-up. Images were obtained of the en-
tire epicardial system using an Imatron
C-150 Ultrafast CT scanner (Imatron,
South San Francisco, CA), with a 100-ms
exposure. The standard acquisition pro-
tocol was used (21). Scanning started
from near the lower margin of the bifur-
cation of the main pulmonary artery. Im-
ages were electrocardiographically
triggered at 80% of the R-R interval, and
30–40 contiguous 3-mm slices were ac-
quired. Calciﬁed coronary artery areas
were identiﬁed as those with a minimum
density of 130 Hounsfeld units (HU) and
a minimum area of three pixels (1.03
mm
2). A calcium score for each region
was calculated by multiplying the area by
the density score (one for 130–199, two
for 200–299, three for 300–399, and 4
for 399 HU). A total CAC score in Ag-
atston units (AU) was calculated by add-
ing up scores for all slices separately for
left main, left anterior descending, cir-
cumﬂex, and right coronary arteries. The
volume scores were calculated using the
volumetric method, which is based on
isotropic interpolation (22).
Statistical methods
Descriptive statistics were reported as
means and frequencies with P values for
differences between groups. ANCOVA,
independent-sample T tests, and Pearson
correlations were used for hypothesis
testing for continuous outcomes, and the

2 test of independence and logistic re-
gression were used for hypothesis testing
for categorical outcomes. Wilcoxon’s
rank-sum tests were used to compare
CAC scores among depressed and non-
depressed participants, type 1 diabetic
participants versus nondiabetic control
subjects, and depressed versus non-
depressed within diabetes type. Due to
thenonnormaldistributionofCACscores
with an abundance of scores of zero, lo-
gistic regression was used to model the
probability of a CAC score 0 for type 1
diabetes status (yes or no), depression
(yes or no), and depression within diabe-
tes category (yes or no), adjusted for age
and sex. A P value of 0.05 was consid-
ered statistically signiﬁcant. SAS 9.1 was
used for all statistical analysis.
RESULTS— Characteristics of the
1,004 participants in this study were as
follows:458type1diabeticpatients(47%
male, aged 44  9 years, type 1 diabetes
duration 29  9 years) and 546 nondia-
beticparticipants(51%male,aged479
years) (Table 1). In our sample, the prev-
alence of depression (as deﬁned by BDI-II
14 and/or antidepressant use) in partic-
ipants with type 1 diabetes was signiﬁ-
cantly higher than that of age- and sex-
adjusted nondiabetic participants (32.1
vs. 16.0%, P  0.0001). A BDI-II score
14 was seen in 17.5% of type 1 diabetic
participants compared with 5.7% in non-
diabetic participants (P  0.0001). Anti-
depressant use was reported in 20.7% of
type 1 diabetic participants compared
with 12.1% of nondiabetic participants
(P  0.0003). The length of antidepres-
sant use was 3.65  3.37 years among
thosewithdiabetesand2.883.08years
for control subjects (P  0.15). Among
thosebeingtreatedfordepression,69.9%
of type 1 diabetic participants and 84.6%
of nondiabetic participants had BDI-II
scores 14 at the time of the study (P 
0.03). Participants with type 1 diabetes
were 3.52 (2.28–5.43) times more likely
to have a BDI-II score 14, were 2.48
(1.83–3.36) times more likely to have a
history of depression than nondiabetic
participants (P  0.0001 for each), and
were 1.89 (1.34–2.67) times more likely
to be on antidepressant medications than
nondiabetic participants (P  0.0003) in
unadjustedanalyses.Inlogisticregression
adjustedforageandsex,participantswith
type 1 diabetes were 3.66 (2.35–5.71)
times more likely to have a BDI-II score
14, were 2.60 (1.90–3.56) times more
likely to have a history of depression than
nondiabetic participants (P  0.0001 for
each), and were 1.99 (1.39–2.84) times
more likely to be on antidepressant med-
ications than nondiabetic participants
(P  0.0002). Participants with diabetes
were also more likely to have moderate
depression(BDI-II20)thanthosewith-
Depression and diabetes
576 DIABETES CARE, VOLUME 32, NUMBER 4, APRIL 2009out diabetes (6.1 vs. 2.4%, P  0.003;
odds ratio 2.65 [95% CI 1.34–5.23], P 
0.005.)
Mean BDI-II score, adjusted for age
and sex, was signiﬁcantly higher in par-
ticipantswithtype1diabetesthaninnon-
diabetic participants (least-squares
meansSE:7.40.3vs.5.00.3;P
0.0001). Depression by BDI-II cut score
and/orantidepressantusewasmoreprev-
alent in women with type 1 diabetes
(37.9%) than in nondiabetic women
(20.5%, P  0.0001) and in men with
type 1 diabetes than in nondiabetic men
(25.5 vs. 11.6%, P  0.0001) (Table 2).
Within type 1 diabetes participants, there
was still a difference between men
(25.5%) and women (37.9%) in the fre-
quency of depression by BDI-II cut score
and/or antidepressant use (P  0.005)
but not when depression was deﬁned
only by a BDI-II score (14.5% for men vs.
20.1% for women, P  0.12). Depression
deﬁned by BDI-II score alone was more
prevalent in women with type 1 diabetes
than in nondiabetic women (20.1 vs.
7.8%, P  0.0001) and in men with type
1 diabetes than in nondiabetic men (14.5
vs. 3.6%, P  0.0001). Women with type
1 diabetes had higher BDI-II scores than
nondiabetic women (7.6  7.3 vs. 5.7 
5.9, P  0.0012), and men with type 1
diabetes had higher BDI-II scores com-
pared with nondiabetic men (7.1  7.3
vs.4.34.8,P0.0001).However,BDI
scores were similar among men and
women with type 1 diabetes (7.1  7.3
vs. 7.6  7.3, P  0.50).
Current GHb was not correlated with
BDI-II score in type 1 diabetic partici-
pants(r0.07,P0.14);however,type
1 diabetic participants with a history of
depression had slightly higher GHb than
those without depression (8.1  1.2 vs.
7.8  1.1%, P  0.013). Type 1 diabetic
participants reporting the presence of at
least one complication (n  209) had sig-
niﬁcantly higher BDI-II scores than those
without complications (8.8  8.2 vs.
6.1  6.1, P  0.0001) and were more
likely to be depressed by BDI-II cut score
(23.4%) than type 1 diabetic participants
withoutcomplications(12.1%,P0.002).
Boththosewith(8.88.2)andthosewith-
out (6.1  6.1) complications had signiﬁ-
cantly higher BDI-II scores than control
subjects (5.0  5.4, P  0.05 both), had
higherprevalenceofdepressionbyBDI-II
scores, BDI-II or antidepressant use, and
antidepressant use alone (online appen-
dixTable A1 [available in the online ap-
pendix at http://care.diabetesjournals.
org/cgi/content/full/dc08-1835/DC1]).
Among those with diabetes, the number
of complications was positively corre-
lated with BDI-II total scores (R  0.25,
P  0.0001).
Of 1,004 participants with BDI-II
scores, 421 patients with type 1 diabetes
and 494 nondiabetic participants had in-
formation available on CAC. Due to the
highly skewed distribution of CAC
scores, we performed logistic regression
modeling with the probability of CAC
0. More participants with type 1 diabe-
tes had CAC compared with nondiabetic
participants (59.6 vs. 47.2%, P 
0.0002).Also,type1diabeticparticipants
who were depressed (BDI-II score 14)
were more likely to have CAC than those
who were not depressed (74.7 vs. 56.6%,
P  0.005) (see online appendix Table
A2). However, this ﬁnding was not the
same among nondiabetic participants
whoweredepressedcomparedwiththose
who were not depressed (44.4 vs. 47.3%,
P  0.77). Deﬁning depression by either
BDI-II score or antidepressant use, type 1
diabetic participants were more likely to
have CAC than those who were not de-
pressed (67.4 vs. 56.1%, P  0.029), and
participants with type 1 diabetes who
were depressed by a BDI 14 were 2.35
(95% CI 1.25–4.39, P  0.01) times
more likely to have a CAC score 0 than
participants with type 1 diabetes without
depression in adjusted analysis (Table 3).
However, there was no relationship be-
tweendepressionbyBDI-IIormedication
Table 1—Participant characteristics
Type 1 diabetic
subjects
Nondiabetic
subjects
n 458 546
Age (years) 43.6  8.9 47.0  8.7
Sex (men) 214 (46.7) 277 (50.8)
Diabetes duration (years) 29.4  8.7
GHb (%) 7.9  1.2 5.6  0.5
Race/ethnicity (% non-Hispanic white) 94.8 86.6
BMI (kg/m
2) 26.8  4.8 26.6  4.8
BDI-II score 7.4  7.3 5.0  5.4
Antidepressant medication use (yes) 93 (20.7) 65 (12.1)
Length of time on antidepressant
medication (years) 3.65  3.37 2.88  3.08
Complications (total) 209 (45.7)
Retinopathy 166 (36.5)
Blindness 27 (6.0)
Neuropathy 97 (21.4)
Amputation 6 (1.3)
Transplantation 6 (1.3)
Presence of CAC (yes) 249/419 (59.4) 233/493 (47.3)
Square root of CAC volume 5.96  9.27 3.26  6.56
Data are means  SD, n (%), or proportion in unadjusted analysis unless indicated otherwise.
Table 2—Prevalence of depression by sex and diabetes
Men Women P All
Type 1 diabetes
BDI-II 14 14.5* 20.1† 0.12 17.5‡
Antidepressant use 13.7 26.8§ 0.0007 20.7‡
BDI-II  14 or medications 25.5* 37.9† 0.005 32.1
No diabetes
BDI-II 14 3.6 7.8 0.032 5.7
Antidepressant use 8.4 16.0 0.007 12.1
BDI-II 14 or medications 11.6 20.5 0.005 16.0
Data are percent, unless otherwise indicated. *P  0.0001 for men with type 1 diabetes vs. men without.
†P  0.0001 for women with type 1 diabetes vs. women without. ‡P  0.0001 for all with type 1 diabetes
compared with all control subjects. §P  0.003 for women with type 1 diabetes vs. women without. P 
0.0003 for all with type 1 diabetes compared with all control subjects.
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DIABETES CARE, VOLUME 32, NUMBER 4, APRIL 2009 577use and a CAC score 0 among non-
diabetic participants (data not shown).
Of the control subjects, 172 had a
partner in the study with diabetes, 179
had a partner in the study without diabe-
tes, and 195 did not have a partner in the
study. There was no difference in preva-
lence of depression by the BDI-II (5.2 vs.
5.0 vs. 6.7%, P  0.76), use of antide-
pressanttherapy(12.8vs.10.6vs.12.3%,
P  0.90) or history of depression by
BDI-II or antidepressant use (15.7 vs.
14.0 vs. 17.4%, P  0.76) among those
with a partner living with diabetes, those
with a nondiabetic partner, and those
without a partner in the study, respec-
tively. There was also no difference in
BDI-II scores among the three types of
control subjects (partner with type 1 dia-
betes[4.674.84],partnerwithouttype
1 diabetes [5.11  5.43], and no partner
in the study [5.16  5.75]; P  0.65).
CONCLUSIONS — Despite pub-
lished data on depression and diabetes,
these results are some of the ﬁrst to spe-
ciﬁcally demonstrate an increased preva-
lence of depression among adults with
type 1 diabetes compared with age- and
sex-matched control subjects. We have
shownthatadultswithtype1diabetesare
more than twice as likely as adults with-
out diabetes to have depression as as-
sessed by BDI-II 14 and/or current
antidepressant use. In this sample, those
withtype1diabetesweremorethanthree
times as likely to have a clinically signiﬁ-
cant score on the BDI-II and almost twice
as likely to be on antidepressant medica-
tion as nondiabetic adults.
Previous literature has estimated the
rate of depression in diabetes to be be-
tween 3.8 and 27.3% (11). In this large
cohort, the prevalence of depression in
type 1 diabetes was 32.1% deﬁned by ei-
ther BDI-II score 14 or antidepressant
medication use. Previous studies have
used a wide variety of measures and cri-
teria for diagnosing depression, and
BDI-II scores of 14 are considered in-
dicative of mild depression. Another pos-
sible explanation is that depression may
be more common in type 1 than in type 2
diabetes, since previous studies have
mainly reported on a mixed sample of
type 1 and type 2 diabetes. In addition,
the inclusion of current antidepressant
medication use as an indicator of depres-
sioninthisstudymaycaptureindividuals
successfully treated for depression who
may no longer score high on depression
assessments.
Findings regarding the association
between depression and hyperglycemia
have been inconsistent in the literature.
Although GHb was not signiﬁcantly cor-
related with BDI-II score in all partici-
pants with type 1 diabetes, we found a
signiﬁcantrelationshipbetweenGHband
a history of depression among partici-
pants with type 1 diabetes. This could be
due in part to the data being cross-
sectional. This lack of signiﬁcant correla-
tion has been seen in previous studies
(23), although a signiﬁcant correlation
has been found elsewhere (2,13).
Our data conﬁrm previous ﬁndings
regarding the association of depression
withcomplicationsofdiabetes.Type1di-
abetic participants reporting the presence
of at least one diabetes complication
scored signiﬁcantly higher on the BDI-II
than participants with type 1 diabetes
with no complications. Coronary artery
disease(CAD)istheleadingcauseofmor-
tality in people with type 1 diabetes (7),
and even mild manifestations of depres-
sion (BDI scores 10) are related to ca-
rotid plaque formation (24), making
depression an important risk factor to
evaluate in patients with type 1 diabetes.
In the Pittsburgh Epidemiology of Diabe-
tes Complications Study, both CAC and
BDI-II score were independently corre-
lated with clinical CAD, and presence of
CAC was predictive of clinical CAD 84
and 71% of the time in men and women,
respectively (4). We report that CACTI
study participants with type 1 diabetes
whoweredepressedweretwotimesmore
likely to have a CAC score 0.
The etiology of the relationship be-
tween type 1 diabetes and depression is
likely to be multifactorial. First, depres-
sion may be a response to the psychoso-
cial stress caused by living with the
demands and constraints imposed by
type 1 diabetes. Second, biological pro-
cesses speciﬁc to diabetes, such as insulin
resistance, changes in brain structures
such as the hippocampus, and inﬂamma-
tory processes, may be related to psycho-
logical symptoms (7). Third, because
both conditions are prevalent, they may
coexist coincidentally. Further research
into the mechanisms involved in the ob-
served relationship is needed.
There are several important strengths
ofthisstudy.Aspreviouslydiscussed,this
is the ﬁrst large-scale assessment of de-
pression in a type 1 diabetes–speciﬁc
populationthatusesacontrolgroupcom-
posed of friends, neighbors, and spouses
to reduce the potential for selection bias
in socioeconomic status and related fac-
tors.Also,theuseofbothawell-validated
depression assessment and antidepres-
sant medication use as indicators of de-
pression improves ascertainment of cases
to include both currently treated and un-
treated depression.
This study has several limitations.
First, the use of a self-report question-
naire is cost- and time-effective, but the
preferred method of psychological diag-
nosis is generally by diagnostic interview
with a psychologist. It has been suggested
that self-report questionnaires may over-
estimate prevalence of depression com-
pared with diagnostic interview (10,14),
and it may be more appropriate to use the
term “clinically signiﬁcant levels of de-
pressive symptoms” in the context of this
study. However, diagnostic interviews
identify major depressive disorder but
may exclude other clinically relevant pre-
sentations. The presence of depressive
symptomatology in general may be better
assessed with a tool such as the BDI-II.
Another limitation of this study is its
cross-sectional nature, meaning that
cause-effect relationships cannot be de-
termined. Since symptoms and therefore
measurements related to both diabetes
and depression can ﬂuctuate signiﬁcantly
over time, a longitudinal design may give
a more accurate picture of this relation-
ship. In type 1 diabetic participants, for
example,GHbcapturedataspeciﬁcpoint
intimemayreﬂectanumberofmediating
circumstancesandisnotasinformativeas
Table 3—Adjusted odds ratios of CAC score >0 by depression and type 1 diabetes status*
Classiﬁcation
Type 1 diabetes
P
No diabetes
P CAC score 0 CAC score 0
Depressed by BDI-II 14 2.35 (1.25–4.39) 0.01 1.02 (0.44–2.36) 0.96
Antidepressant use 1.35 (0.78–2.34) 0.37 1.29 (0.70–2.37) 0.41
BDI or medications 1.80 (1.11–2.92) 0.017 1.12 (0.65–1.91) 0.69
Data are odds ratio (95% CI), unless otherwise indicated. *Adjusted for age, sex, and duration of diabetes in
type 1 diabetic subjects and age and sex for control subjects.
Depression and diabetes
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is possible that a stronger correlation be-
tween glycemic control and depression in
type 1 diabetes would be found with a
longitudinal study design.
Depression can severely compromise
day-to-day functioning and, in the ab-
sence of treatment, tends to follow a
chronic or relapsing course (8). In addi-
tion to the detrimental effects on essential
daily self-care behaviors, there are signif-
icant health care costs associated with de-
pression in patients with diabetes (25).
Screening patients with type 1 diabetes
fordepressivesymptomsisvital.Ourdata
also suggest that appropriate intervention
is especially important in patients with
complications of diabetes, as they are
especially likely to suffer from depres-
sive symptoms according to our data.
Treatment of depression should be ac-
companied by prospective assessment
of its efﬁcacy in improving mental
health symptoms as well as diabetes
health outcomes.
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